Vimarsana
Biggest News Aggregation in the World

Page 4 - Thomas Biegi News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Thomas Biegi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Thomas Biegi Today - Breaking & Trending Today

EQS-News: MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023 - Vimarsana News

EQS-News: MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023

EQS-News: MorphoSys AG / Key word(s): Change in Forecast MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross ...

MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Gui - Vimarsana News

MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Gui

EQS-News: MorphoSys AG / Key word(s): Change in ForecastMorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023 25.10.2023 / 10:50 CET/CESTThe issuer is solely responsible for the content of this announcement.Planegg/Munich, Germany, October 25, 2023 Mo...

MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer - Vimarsana News

MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer 12.09.2023 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, September 12, 2023 MorphoSys Receiv...

EQS-News: MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer - Vimarsana News

EQS-News: MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

EQS-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys Receives U.S. FDA Fast Track Designation for Tulmime...

MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer - Vimarsana News

MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

EQS-News: MorphoSys AG / Key word: Miscellaneous MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer 12.09.2023 / 22:01...